CL2017001292A1 - 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139 - Google Patents

4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139

Info

Publication number
CL2017001292A1
CL2017001292A1 CL2017001292A CL2017001292A CL2017001292A1 CL 2017001292 A1 CL2017001292 A1 CL 2017001292A1 CL 2017001292 A CL2017001292 A CL 2017001292A CL 2017001292 A CL2017001292 A CL 2017001292A CL 2017001292 A1 CL2017001292 A1 CL 2017001292A1
Authority
CL
Chile
Prior art keywords
gpr139
benzotraizines
modulators
dihydro
oxo
Prior art date
Application number
CL2017001292A
Other languages
English (en)
Inventor
Betty Lam
Stephen Hitchcock
Holger Monenschein
Holly Reichard
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2017001292A1 publication Critical patent/CL2017001292A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO PARA TRATAR UNA ENFERMEDAD, TRASTORNO O AFECCIÓN ASOCIADO CON GPR139 UTILIZANDO COMPUESTOS DE FÓRMULA 1, LOS CUALES SON AGONISTAS DE GPR1 39, CIERTOS COMPUESTOS ENGLOBADOS POR LA FÓRMULA 1, COMPOSICIONES FARMACÉUTICAS DE ESTOS, PROCESOS PARA PREPARAR LOS COMPUESTOS E INTERMEDIOS DE ESTOS.</p>
CL2017001292A 2014-11-20 2017-05-19 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139 CL2017001292A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
CL2017001292A1 true CL2017001292A1 (es) 2018-02-16

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001292A CL2017001292A1 (es) 2014-11-20 2017-05-19 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (es)
EP (2) EP3221298B1 (es)
JP (2) JP6637501B2 (es)
KR (1) KR102582021B1 (es)
CN (2) CN107108531B (es)
AU (1) AU2015349866B2 (es)
BR (1) BR112017010311A2 (es)
CA (1) CA2968242C (es)
CL (1) CL2017001292A1 (es)
CO (1) CO2017005959A2 (es)
CR (1) CR20170275A (es)
CY (2) CY1122613T1 (es)
DK (2) DK3221298T3 (es)
DO (1) DOP2017000120A (es)
EA (1) EA033728B1 (es)
EC (1) ECSP17038999A (es)
ES (2) ES2734735T3 (es)
GE (1) GEP20196961B (es)
HR (2) HRP20212009T1 (es)
HU (2) HUE057451T2 (es)
IL (1) IL252311B (es)
JO (1) JO3719B1 (es)
LT (2) LT3221298T (es)
MA (1) MA40993B1 (es)
MD (1) MD3221298T2 (es)
MX (1) MX2017006448A (es)
MY (1) MY187423A (es)
NZ (1) NZ732208A (es)
PE (1) PE20170899A1 (es)
PH (1) PH12017500920B1 (es)
PL (2) PL3536324T3 (es)
PT (2) PT3536324T (es)
RS (2) RS62563B1 (es)
SG (1) SG11201704002UA (es)
SI (2) SI3221298T1 (es)
TN (1) TN2017000196A1 (es)
TW (1) TWI684590B (es)
UA (1) UA120375C2 (es)
UY (1) UY36406A (es)
WO (1) WO2016081736A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
CA3121108A1 (en) * 2018-10-16 2020-04-23 The Scripps Research Institute Methods related to opioid therapeutics
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
AR119971A1 (es) 2019-09-16 2022-01-26 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
US20230227416A1 (en) * 2020-05-08 2023-07-20 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
WO2022058791A1 (en) 2020-09-21 2022-03-24 Takeda Pharmaceutical Company Limited Treatment for schizophrenia
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
WO2023165263A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
WO2023165262A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
DE3752141T2 (de) 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
ATE108791T1 (de) 1987-11-04 1994-08-15 Beecham Group Plc Neue 4-oxobenzotriazine und 4-oxochinazoline.
US7582766B2 (en) 2003-06-09 2009-09-01 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
MXPA06001081A (es) 2003-07-31 2006-04-24 Irm Llc Compuestos biciclicos y composiciones como inhibidores de pdf.
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
MX2009010218A (es) * 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
JP2016515138A (ja) * 2013-03-14 2016-05-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｇｐｒ１３９の生理的リガンド
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
AU2015349866A1 (en) 2017-06-15
EP3536324B1 (en) 2021-10-06
CO2017005959A2 (es) 2017-10-20
KR20170084324A (ko) 2017-07-19
WO2016081736A1 (en) 2016-05-26
US20190070187A1 (en) 2019-03-07
PT3536324T (pt) 2021-11-10
MA40993B1 (fr) 2019-07-31
TN2017000196A1 (en) 2018-10-19
UA120375C2 (uk) 2019-11-25
JO3719B1 (ar) 2021-01-31
PE20170899A1 (es) 2017-07-12
JP6918088B2 (ja) 2021-08-11
BR112017010311A2 (pt) 2017-12-26
CN112062730B (zh) 2023-09-29
US20160145218A1 (en) 2016-05-26
CA2968242C (en) 2022-11-08
EP3221298A1 (en) 2017-09-27
MY187423A (en) 2021-09-22
JP2017535559A (ja) 2017-11-30
US11173161B2 (en) 2021-11-16
US9770450B2 (en) 2017-09-26
LT3536324T (lt) 2021-12-10
US20170348319A1 (en) 2017-12-07
IL252311A0 (en) 2017-07-31
HUE057451T2 (hu) 2022-05-28
PH12017500920A1 (en) 2017-11-20
EA033728B1 (ru) 2019-11-20
ECSP17038999A (es) 2017-10-31
US10561662B2 (en) 2020-02-18
NZ732208A (en) 2023-02-24
SG11201704002UA (en) 2017-06-29
LT3221298T (lt) 2019-08-12
CN112062730A (zh) 2020-12-11
CY1124929T1 (el) 2023-01-05
US9556130B2 (en) 2017-01-31
HUE044145T2 (hu) 2019-09-30
US20200129518A1 (en) 2020-04-30
CY1122613T1 (el) 2021-05-05
HRP20212009T1 (hr) 2022-04-01
AU2015349866B2 (en) 2020-12-03
TWI684590B (zh) 2020-02-11
DK3221298T3 (da) 2019-06-24
SI3536324T1 (sl) 2021-12-31
GEP20196961B (en) 2019-03-25
MX2017006448A (es) 2017-09-12
TW201625566A (zh) 2016-07-16
DK3536324T3 (da) 2021-10-25
CA2968242A1 (en) 2016-05-26
JP6637501B2 (ja) 2020-01-29
CR20170275A (es) 2017-10-30
SI3221298T1 (sl) 2019-10-30
JP2020063285A (ja) 2020-04-23
PT3221298T (pt) 2019-06-28
MD3221298T2 (ro) 2019-10-31
IL252311B (en) 2020-07-30
EP3221298B1 (en) 2019-04-03
RS62563B1 (sr) 2021-12-31
DOP2017000120A (es) 2017-06-15
ES2897545T3 (es) 2022-03-01
EP3536324A1 (en) 2019-09-11
RS59078B1 (sr) 2019-09-30
UY36406A (es) 2016-06-30
ES2734735T3 (es) 2019-12-11
MA40993A (fr) 2017-09-27
PL3221298T3 (pl) 2019-10-31
EA201791096A1 (ru) 2017-11-30
CN107108531A (zh) 2017-08-29
PL3536324T3 (pl) 2022-02-07
US10159677B2 (en) 2018-12-25
US20170095480A1 (en) 2017-04-06
PH12017500920B1 (en) 2017-11-20
KR102582021B1 (ko) 2023-09-22
CN107108531B (zh) 2020-10-20
HRP20191003T1 (hr) 2019-08-23

Similar Documents

Publication Publication Date Title
CL2017001292A1 (es) 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139
CL2017001171A1 (es) Peptidos macrocíclicos útiles como inmunomoduladores
CL2017001393S1 (es) Automovil
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
CL2017001185S1 (es) Automovil
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CL2017001046A1 (es) Inhibidoes del bromodominio
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
UY37018A (es) Inhibidores bicíclicos de pad4
MA46373A (fr) Composés utilisés comme modulateurs de ror gamma
BR112016029076A8 (pt) Modulação de atividade de complemento
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CL2017000152A1 (es) Derivados de isoindolinona
CR20170005A (es) Derivados de insoindolina
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
CL2017000151A1 (es) Derivados de piridona
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
DK3377094T3 (da) Virulenssvækkede bakterier til behandling af ondartede solide tumorer